Pang Liwei, Zhang Yan, Wang Yuwen, Kong Jing
Department of Biliary and Minimally Invasive Surgery, China Medical University Shengjing Hospital Shenyang, Liaoning, China.
Department of Surgery, Sixth People's Hospital of Shenyang, Liaoning, China.
Braz J Med Biol Res. 2018;51(6):e7411. doi: 10.1590/1414-431x20187411. Epub 2018 May 21.
The exact pathogenesis of gallbladder adenomyomatosis is still lacking and some controversies over its diagnosis and treatment exist. Originally recognized as a precancerous lesion, adenomyomatosis is currently recognized by recent studies as a benign alteration of the gallbladder that is often associated with cholecystitis and cholecystolithiasis. Gallbladder carcinoma is an extremely malignant disease with a 5-year survival rate of less than 5%. Therefore, it is important to diagnose, differentiate, and confirm the relationship between adenomyomatosis and early-stage gallbladder carcinoma. However, the early clinical symptoms of adenomyomatosis are extremely similar to those of gallbladder stones and cholecystitis, increasing the difficulty to identify and treat this disease. This article summarizes the research progress on gallbladder adenomyomatosis, aiming to improve the understanding of the pathogenesis of adenomyomatosis and further provide insight for its clinical diagnosis and treatment.
胆囊腺肌增生症的确切发病机制尚不清楚，关于其诊断和治疗存在一些争议。腺肌增生症最初被认为是一种癌前病变，目前最新研究认为它是胆囊的一种良性改变，常与胆囊炎和胆囊结石相关。胆囊癌是一种恶性程度极高的疾病，5年生存率低于5%。因此，诊断、鉴别并确认腺肌增生症与早期胆囊癌之间的关系非常重要。然而，腺肌增生症的早期临床症状与胆结石和胆囊炎极为相似，增加了该病的识别和治疗难度。本文总结了胆囊腺肌增生症的研究进展，旨在增进对腺肌增生症发病机制的理解，并为其临床诊断和治疗提供进一步的见解。
